These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 18240669)

  • 1. Adverse effects of bisphosphonates: current issues.
    Diel IJ; Bergner R; Grötz KA
    J Support Oncol; 2007; 5(10):475-82. PubMed ID: 18240669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid.
    García Sáenz JA; López Tarruella S; García Paredes B; Rodríguez Lajusticia L; Villalobos L; Díaz Rubio E
    Med Oral Patol Oral Cir Bucal; 2007 Sep; 12(5):E351-6. PubMed ID: 17767097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety profile of intravenous bisphosphonates.
    Mehrotra B
    Semin Oncol; 2007 Dec; 34(6 Suppl 4):S24-7. PubMed ID: 18068487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer: bisphosphonate therapy for metastatic bone disease.
    Body JJ
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6258s-6263s. PubMed ID: 17062710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonate treatment recommendations for oncologists.
    von Moos R
    Oncologist; 2005; 10 Suppl 1():19-24. PubMed ID: 16264109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
    King AE; Umland EM
    Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.
    Grewal VS; Fayans EP
    Todays FDA; 2008 Aug; 20(8):38-41, 43-6. PubMed ID: 18767452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety considerations with bisphosphonates for the treatment of osteoporosis.
    Strampel W; Emkey R; Civitelli R
    Drug Saf; 2007; 30(9):755-63. PubMed ID: 17722968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients.
    Body JJ; Coleman R; Clezardin P; Ripamonti C; Rizzoli R; Aapro M;
    Eur J Cancer; 2007 Mar; 43(5):852-8. PubMed ID: 17258449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?
    Brown JJ; Ramalingam L; Zacharin MR
    Clin Endocrinol (Oxf); 2008 Jun; 68(6):863-7. PubMed ID: 18221397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy.
    Estilo CL; Van Poznak CH; Wiliams T; Bohle GC; Lwin PT; Zhou Q; Riedel ER; Carlson DL; Schoder H; Farooki A; Fornier M; Halpern JL; Tunick SJ; Huryn JM
    Oncologist; 2008 Aug; 13(8):911-20. PubMed ID: 18695259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients.
    Walter C; Al-Nawas B; du Bois A; Buch L; Harter P; Grötz KA
    Cancer; 2009 Apr; 115(8):1631-7. PubMed ID: 19156913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates?
    Diel IJ; Fogelman I; Al-Nawas B; Hoffmeister B; Migliorati C; Gligorov J; Väänänen K; Pylkkänen L; Pecherstorfer M; Aapro MS
    Crit Rev Oncol Hematol; 2007 Dec; 64(3):198-207. PubMed ID: 17855108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens.
    Conte P; Guarneri V
    Oncologist; 2004; 9 Suppl 4():28-37. PubMed ID: 15459427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
    Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
    Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of bisphosphonates in early breast cancer.
    Paterson AH
    Oncologist; 2006; 11 Suppl 1():13-9. PubMed ID: 16971735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing metastatic bone pain: the role of bisphosphonates.
    Gralow J; Tripathy D
    J Pain Symptom Manage; 2007 Apr; 33(4):462-72. PubMed ID: 17397707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance and impact of bisphosphonate-induced acute phase responses.
    Olson K; Van Poznak C
    J Oncol Pharm Pract; 2007 Dec; 13(4):223-9. PubMed ID: 18045781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal management of metastatic bone disease.
    Major P
    Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.